Atezolizumab was also the first FDA-approved PD-L1 inhibitor (human IgG1 mAb) used to treat UC, TNBC, NSCLC, and SCLC (small cell lung cancer). This evidence concerns the gene CD274 and non-small cell lung carcinoma.